Merck avoided billions in U.S. tax by offshoring Keytruda profits - senator
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Merck (MRK) Tops Analyst Estimates on Strong Keytruda, Gardasil, and Bridion Sales
July 28, 2022 2:03 PM EDTMerck's (NYSE: MRK) shares dipped in the early part of Thursday's session after it reported second-quarter earnings.
Profit and revenue topped analyst expectations, but the company's shares fell as low as $87.42 after guidance disappointed investors. The stock has since regained the majority of its initial losses.
Merck posted earnings of $1.87, $0.19 better than the analyst estimate of... More
